Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158824 | 0.93 | HTR6 (0.51) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5161560 | 0.93 | SLC6A2 (0.47) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5158432 | 0.93 | HTR6 (0.42) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5158358 | 0.91 | HTR6 (0.46) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5158767 | 0.90 | SLC6A2 (0.46) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5161532 | 0.89 | HTR6 (0.43) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5156227 | 0.89 | REN (0.45) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5158982 | 0.88 | HTR6 (0.40) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5156467 | 0.88 | SLC6A2 (0.47) | RENHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5158423 | 0.87 | HTR6 (0.48) | RENHTR6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | REN 610/4885HTR6 406/4885SLC6A2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.